CRDL trades 669.2% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CRDL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Cardiol Therapeutics Inc. (CRDL) has a Wall Street consensus price target of $8.00, based on estimates from 2 covering analysts. With the stock currently trading at $1.04, this represents a potential upside of +669.2%. The company has a market capitalization of $116M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRDL trades at a trailing P/E of -3.8x. Analysts expect EPS to grow -42.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. | $355M | $3.25 | $5.00 | +53.8% | Buy | — | 19 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
ARWRArrowhead Pharmaceuticals, Inc. | $11.1B | $78.89 | $84.00 | +6.5% | Buy | — | 21 |
TELATELA Bio, Inc. | $33M | $0.74 | — | — | — | — | — |
MDGLMadrigal Pharmaceuticals, Inc. | $11.8B | $512.65 | $656.00 | +28.0% | Buy | — | 23 |
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.32 | $33.67 | +33.0% | Buy | 65.1x | 37 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
ARDXArdelyx, Inc. | $1.4B | $5.55 | $17.00 | +206.3% | Buy | — | 16 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
PFEPfizer Inc. | $138.1B | $24.29 | $26.75 | +10.2% | Hold | 8.2x | 39 |
Quick answers to the most common questions about buying CRDL stock.
The consensus Wall Street price target for CRDL is $8, representing 669.2% upside from the current price of $1.04. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CRDL has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 669.2% upside from current levels.
CRDL's current price is $1.04 with a consensus target of $8 (669.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for CRDL, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
CRDL is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRDL stock forecast based on 2 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CRDL, with a "Buy" consensus rating and $8 price target (669.2% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRDL analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.